Krystal Biotech, Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Krystal Biotech, Inc. on October 22, 2025. The report details a significant commercial milestone for the company's wholly owned subsidiary, Krystal Biotech Japan KK.
Key Financial Metrics
The filing does not provide specific financial statements, revenue figures, profit data, cash flow, margins, debt levels, or liquidity metrics. The only financial data disclosed is the pricing of the company's product in Japan.
- Product Price: VYJUVEK (beremagene geperpavec) is listed on Japan's National Health Insurance (NHI) Drug Price List at 2,955,232.7 yen per unit.
Material Changes
Effective October 22, 2025, Krystal Biotech Japan KK commenced the commercial launch of VYJUVEK in Japan for the treatment of dystrophic epidermolysis bullosa. This launch follows the drug's inclusion on the NHI Drug Price List on the same date.
Outlook and Management Commentary
The filing states that the report is being furnished for informational purposes only. No forward-looking guidance, risk factors, contingencies, or unusual items are discussed in this specific document.
Investor Verification Checklist
- Verify the commercial launch date of VYJUVEK in Japan (October 22, 2025).
- Confirm the NHI listing price of 2,955,232.7 yen per unit.
- Review subsequent filings for actual sales volume and revenue impact from the Japanese market.
- Check for any regulatory updates regarding the treatment of dystrophic epidermolysis bullosa in Japan.